Solid pseudopapillary tumor of the pancreas: A population-based comparison with pancreatic ductal adenocarcinoma

Objective: Solid-pseudopapillary tumor of the pancreas (SPTP) is a rare neoplasm that has been investigated only in individual case series from individual institutions. Here, the goal was to perform a population-based analysis of these rare tumors.Methods: A query of the Surveillance, Epidemiology, and End Results (SEER) database was made for patients with malignant SPTP and pancreatic ductal adenocarcinoma (PDAC) from 2001-2010. The primary outcome measure was five-year overall survival. Cox regression analyses were performed using age, race, gender, tumor location, stage of tumor, and histologic type.Results: 107 patients with SPTP and 53,353 with PDAC were identified for study. Patients with SPTP were younger (p<0.001), more often female (p<0.001), and less commonly white (p<0.001) than those with PDAC. SPTPs were also more frequently located in the tail (p<0.001), of lesser stage (p<0.001), and more likely to undergo surgical treatment (p<0.001) than PDAC. The overall 5-year survival was 84.7% for SPTP and 2.8% for PDAC. For those patients who underwent surgical treatment, 5-year overall and cancer-specific survival was 92.7% and 95.9% for SPTP and 13.5% and 16.7% for PDAC, respectively.Conclusion: SPTP is a rare pancreatic neoplasm found more commonly in young women in the tail of the pancreas and is associated with a significantly more favorable prognosis than PDAC. [Arch Clin Exp Surg 2016; 5(3.000): 148-153